Mehta Analysis: BMS/Celgene Merger Shows Big Pharma Is Stuck In Wrong Groove
Bristol-Myers Squibb executives are justifying the acquisition of Celgene in terms that have been well-rehearsed through the history of big pharma mergers. But they are failing to consider radical changes to the environment in which pharma operates, argues Viren Mehta of Mehta Partners LLC.
You may also be interested in...
Deal Watch: Oncternal Goes Public Via Reverse Merger With GTx
All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.
Big Pharma At The Senate: When It Comes To Yes Or No Questions, There Are Still A Few Maybes
Celgene/Bristol: Happy Union Or Runaway Bride?
Wellington, the largest institutional shareholder in Bristol, and activist firm Starboard both have publicly opposed the Bristol/Celgene merger but the strong crossover of investors in both biopharmas suggests the deal will still obtain approval.